Shandong Boan Biotech-h (6955.HK) traded up 1.09 % during a 24 hours period ending at 06:06 PM Central Europe on Tuesday 27th. One Shandong Boan Biotech-h stock can currently be bought for about HKD 3.12 on popular exchanges. Current supply of Shandong Boan Biotech-h stocks is 614.2 mn. Shandong Boan Biotech-h has a current market capitalization of HKD 2 bn and approximately HKD 1.4 mn worth of Shandong Boan Biotech-h was traded on exchanges in the last 24 hours. Since last month end, Shandong Boan Biotech-h has traded 17.85 % up. Simple moving average of last 200 days is at HKD 5.71. The highest price of past 52 weeks was recorded at HKD 11.2 on 11/27/2025. 52 weeks low was at HKD 2.4 on 09/18/2026.
Here is how related stocks have performed in the past 24 hours:
Qingcloud (688316.SS) traded flat 0 % and now trades at CNY 44. Current market capitalisation for Qingcloud is CNY 2 bn. During the trading session, the cloud‑compute leasing segment experienced a partial uptick, prompting a notable rise for several stocks. Among these, the shares of QingCloud Technologies Corp. were among those that moved upward, following the broader trend. Reports cited the statement of Amazon’s chief executive, indicating that the company’s cloud‑computing capacity is nearing full utilisation by the end of 2027, with many orders scheduled for 2028. This development underscores the growing demand for artificial‑intelligence infrastructure. The market reaction to these announcements reflected increased confidence in the sector, with QingCloud Technologies Corp. benefitting from the positive sentiment surrounding the broader cloud‑computing landscape.
Forbon (300387.SZ) traded flat 0 % and now trades at CNY 6.76. Forbon has a market capitalisation of CNY 2 bn. Current price/earnings ratio for Forbon is 39.16.
Wuhan Citms (688038.SS) traded flat 0 % and now trades at CNY 16.97. Current market capitalisation for Wuhan Citms is CNY 2 bn. Wuhan CITMS Technology Co., Ltd. reported its third‑quarter earnings for 2026, noting a strengthening of revenue and profit figures compared with the previous year. The company highlighted continued growth in its AI‑edge chip segment, underscoring the successful deployment of its RK3566 processor in emerging robot and industrial applications. The firm also mentioned the inclusion of the Microduck robot in its quarterly report, noting that the product has attracted market attention and is supported by the company’s chip architecture. Despite challenges related to raw‑material supply constraints that slightly impacted the quarter’s sales performance, management expressed confidence that production orders will recover in the next period. The company maintained its stance on maintaining a positive outlook for its AI‑oT portfolio and reinforced its commitment to shareholder returns through a proposed dividend plan.
Jiangsu Yunyong Electronics And (688060.SS) traded flat 0 % and now trades at CNY 33.06. Current market capitalisation for Jiangsu Yunyong Electronics And is CNY 2 bn.
Jiangsu Recbio -H (2179.HK) traded flat 0 % and now trades at HKD 3.8. Current market capitalisation for Jiangsu Recbio -H is HKD 2.4 bn.
About Shandong Boan Biotech-h
Shandong BoAn Biotechnology Co., Ltd. is a fully-integrated biopharmaceutical company operating in the health care sector. The company specializes in conducting research and development, manufacturing, and commercializing therapeutic antibodies, with a primary focus on key therapeutic areas such as oncology, metabolism, autoimmunity, and ophthalmology.